10:46 AM EDT, 06/11/2025 (MT Newswires) -- Jaguar Health ( JAGX ) said Wednesday that the first site for the field study of Canalevia-CA1, crofelemer delayed-release tablets, has been established.

The US Food and Drug Administration has conditionally approved the drug for the treatment of diarrhea caused by chemotherapy in dogs, according to the company.

Jaguar Health ( JAGX ) said it plans to obtain full approval for the drug and expand authorization for crofelemer to include treatment of general, non-infectious diarrhea in dogs.

The company said it is in talks with potential partners over funds to develop and commercialize crofelemer in the US and/or globally.

Price: 3.86, Change: +0.03, Percent Change: +0.81